Clinical Trial Inspectors May Take On Greater Compliance Role In FDA Reorg
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Bioresearch Monitoring program may oversee aspects of drug post-marketing requirements and REMS as part of broader agency reorganization, but BIMO inspectors won’t be commodity-specific.